The study was not set up to look at any differences between the two. The Pfizer/BioNTech was available first so there is more data, but the Oxford/AstraZeneca was mostly used in the older age group. The numbers were very small and there was uncertainty over their significance, said the researchers. It is an important point but we cant at the moment say anything about that, he said. The study, released as a preprint ahead of peer review, is hosted on the University of Edinburgh website (bit.ly/3aHQXzh), and has been uploaded to the SSRN preprint site, according to a University statement.
Pfizer has made many changes to its primal research design.
( z0 change :quant ( z1 many ) :ARG0 ( z2 company :name ( z3 name :op "Pfizer" ) ) :ARG1 ( z4 design :ARG0 z2 :ARG1 ( z5 research :mod ( z6 primal ) ) ) )
(z0 / change-01
    :quant (z1 / many)
    :ARG0 (z2 / company
              :name (z3 / name
                        :op1 "Pfizer"))
    :ARG1 (z4 / design-01
              :ARG0 z2
              :ARG1 (z5 / research-01
                        :mod (z6 / primal))))
Pfizer has made many changes to its primal research design .
z2 :name z3
z3 :op1 0
z0 :quant z1
z0 :ARG0 z2
z5 :mod z6
z4 :ARG1 z5
z0 :ARG1 z4
z4 :ARG0 z2